I think I mentioned that Leronlimab was bought years ago.
Leronlimab (previously known as PRO140) is a humanized IgG4 targeting CCR5 which CytoDyn is progressing through multiple stages of clinical development for a variety of diseases, namely CCR5-tropic HIV infection, metastatic TNBC, metastatic colorectal cancer, nonalcoholic steatohepatitis (NASH), and graft-versus-host disease (GvHD) with a variety of preclinical studies ongoing in an oncology setting [66].
CytoDyn acquired leronlimab from Progenics Pharmaceuticals in 2012.